Indegene Limited reported a strong performance for the quarter ended September 30, 2025, with revenue rising 17% year-on-year to Rs 804.2 crore. Sequentially, revenue grew 5.7%. The company posted a profit after tax of Rs 102.1 crore, compared to Rs 91.7 crore in the same quarter last year.
The life-sciences tech firm maintained a healthy margin profile, with adjusted EBITDA margin at 18.2% and PAT margin at 12.7% for the quarter. Adjusted EBITDA stood at Rs 146.1 crore, up from Rs 126.7 crore a year ago.
Indegene also announced two strategic acquisitions during the quarter — US-based BioPharm, a marketing services agency with expertise in omni-channel and targeted HCP engagement, and UK-based WARN & Co., a transformation consulting firm. Both deals are expected to strengthen Indegene’s global capabilities across digital and enterprise transformation.
The company highlighted continued deal momentum, healthy renewals pipeline, and strong traction across digital-first offerings including AI-enabled platforms.
Chairman & CEO Manish Gupta said the quarter marked the fourth straight period of strong growth driven by deal execution and pipeline strength. CFO Suhas Prabhu noted progress across business development, newer delivery models, and M&A initiatives, and expects tangible benefits going ahead.
